Medical Marijuana (MJNA) Capitalizes on the $450 Million CBD Market
December 14th, 2016
News, Top News
Tetrahydrocannabinol – or THC – may be the most popular cannabinoid thanks to its ability to produce a ‘high’ for users, but cannabidiol – or CBD – has become the focus of the medical community. Since cannabis remains illegal in the U.S. on a federal level, non-psychoactive hemp plants have become a popular source of CBDs that can be used for therapeutic or wellness purposes ranging from pain relief to skin care.
According to the Hemp Industry Association, annual retail sales of hemp products grew at a 10.4% clip to surpass $570 million in 2015. Industrial applications still account for most of the market, but hemp foods, personal care products, supplements, and hemp-derived CBD products have experienced a growing market share. Hemp Business Journal’s CBD Report projects that hemp-based CBD products will become a $450 million market by 2020.
In this article, we will look at how Medical Marijuana Inc. (OTC Pink: MJNA) is well positioned to capitalize on this market’s explosive growth over the coming quarters.
CBD’s Wellness Role
The Hemp Business Journal’s CBD Report highlights the growing role of CBDs for wellness, projecting that approximately 40% of the $450 million market will be devoted to pharmaceuticals by 2020. Charlotte’s Web is perhaps the best example of a CBD-dominant form of cannabis that could potentially alleviate the symptoms of epilepsy and other medical conditions, but hemp-based alternatives could provide a legal pathway to the same outcomes.
For example, GW Pharmaceuticals plc’s (NASDAQ: GWPH) Epidiolex is a 99% CBD and 0.1% THC pharmaceutical compound that’s undergoing FDA-sanctioned clinical trials for the treatment of Dravet Syndrome – a rare form of epilepsy that’s difficult to treat. The company’s Sativex – a pharmaceutical compound containing a 1:1 ratio of CBD and THC – was also approved by Canadian authorities for the treatment of pain associated with multiple sclerosis.
Google Scholar has archived more than 2,000 research papers discussing CBD’s role in the treatment of various medical conditions this year. With hemp-based CBDs widely available to researchers in the United States, a growing number of researchers have become interested in the cannabinoid’s potential across a spectrum of diseases. These published papers could eventually sway the medical community and open the door to new therapeutics.
Building a Global Presence
Medical Marijuana Inc. is building a global footprint in the CBD industry with its Real Scientific Hemp Oil (“RSHO”) – a hemp-derived pure CBD oil that’s available over the counter – until the scientific community catches up. With distribution across all of the United States and numerous countries around the world including Mexico, Columbia, and Brazil, the company has become a leader in providing pure CBD oils that have been shown to be effective in treating epilepsy, pain, and other conditions.
In addition to its over-the-counter products, the company has a 45.5% stake in AXIM Biotech Inc. (OTCQB: AXIM), which owns the patent for chewing gum as a delivery method for cannabinoids. The company will soon start Phase III clinical trials for their combination CBD/THC gum MedChew™ RX for the treatment of spasticity associated with multiple sclerosis and, once approved by the EMA, the gum will be offered across the European Union.
The company also holds a portfolio of other companies focused on distributing and marketing CBDs and advancing the science of cannabinoids. For example, its Kannaway subsidiary is focused on marketing cannabinoids throughout the United States with a variety of different products targeting areas like skincare, while its Kannalife subsidiary holds an exclusive license from the NIH for the commercialization of US Patent 6,630,507 for neuroprotection.
Recently, Medical Marijuana Inc. was featured in a Forbes article discussing growth in the CBD market. In the article, Debra Borchardt, a cannabis-focused contributor, outlines the state of the market and the company’s leadership position within the market. The company makes it clear that its products are derived from high-quality hemp grown in Austria with products that include Dixie Botanicals and Real Scientific CBD Oils.
Medical Marijuana Inc.’s (OTC Pink: MJNA) focus on over-the-counter pure CBD oil and pharmaceutical products that take advantage of cannabinoids make it one of the most advanced companies in the space. Investors looking for a diversified play on CBDs that’s already generating tangible revenue may want to take a closer look at the company and its many subsidiaries focused on all areas of the industry.
For more information, visit the company’s website at www.medicalmarijuanainc.com.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.